RELENZA

LOE Approaching

zanamivir

NDAINHALATIONPOWDERPriority Review
Approved
Jul 1999
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
15

Mechanism of Action

Neuraminidase Inhibitors

Pharmacologic Class:

Neuraminidase Inhibitor

Clinical Trials (5)

NCT04494412Phase 2Recruiting

An Intravenous (IV) Zanamivir Pharmacokinetics (PK) Study in Hospitalized Neonates and Infants With Influenza Infection

Started Nov 2022
12 enrolled
Influenza, HumanArthralgia
NCT02377401Phase 1Completed

Pharmacokinetics of Zanamivir After Single and Repeated Dose Infusion Administration in Healthy Chinese Adults

Started Apr 2015
24 enrolled
Influenza, Human
NCT01527110Phase 3Completed

A Study of Intravenous Zanamivir in the Treatment of Hospitalized Patients With Influenza Infection

Started Jan 2012
21 enrolled
Influenza, Human
NCT01353768N/ACompleted

Zanamivir Aqueous Solution Compassionate Use Program Retrospective Chart Review Study

Started Jul 2011
113 enrolled
Infections, Respiratory Tract
NCT01462487N/ACompleted

Safety of Inhaled Zanamivir in Pregnancy

Started Jul 2011
1 enrolled
Influenza, Human